An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 06 Aug 2019 Planned End Date changed from 25 Jul 2019 to 7 Aug 2019.
- 24 Jul 2019 Planned End Date changed from 8 Jul 2019 to 25 Jul 2019.